Opko Licenses Alzheimer's Diagnostic Technology to LabCorp
April 06, 2012
Opko Licenses Alzheimer's Diagnostic Technology to LabCorp
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Opko Health Revamping Peptoid-Based Diagnostic Platform, Prepping Alzheimer's Test for Market
July 27, 2012 / ProteoMonitor - Opko Inks Deal with BMS to ID Response Markers for Orencia; Again Retools Peptoid-Based Dx Platform
January 18, 2013 / ProteoMonitor - ASU's Biodesign Institute Wins $30M DoD Contract for Immunosignature-Based Pathogen Detection Chip
April 27, 2012 / ProteoMonitor - Opko Health, Scripps Institute Developing Antibody-Based Alzheimer's Diagnostic
January 7, 2011 / ProteoMonitor - Opko Licenses Kallikrein Proteins as Biomarkers for Prostate Cancer
January 30, 2012 / ProteoMonitor